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Abstract
Background: Survival of people with HIV-2 and HTLV-1 infection is better than that of HIV-1 infected people, but long-term
follow-up data are rare. We compared mortality rates of HIV-1, HIV-2, and HTLV-1 infected subjects with those of retrovirus-
uninfected people in a rural community in Guinea-Bissau.
Methods: In 1990, 1997 and 2007, adult residents (aged $15 years) were interviewed, a blood sample was drawn and
retroviral status was determined. An annual census was used to ascertain the vital status of all subjects. Cox regression
analysis was used to estimate mortality hazard ratios (HR), comparing retrovirus-infected versus uninfected people.
Results: A total of 5376 subjects were included; 197 with HIV-1, 424 with HIV-2 and 325 with HTLV-1 infection. The median
follow-up time was 10.9 years (range 0.0–20.3). The crude mortality rates were 9.6 per 100 person-years of observation (95%
confidence interval 7.1-12.9) for HIV-1, 4.1 (3.4–5.0) for HIV-2, 3.6 (2.9–4.6) for HTLV-1, and 1.6 (1.5–1.8) for retrovirus-
negative subjects. The HR comparing the mortality rate of infected to that of uninfected subjects varied significantly with
age. The adjusted HR for HIV-1 infection varied from 4.0 in the oldest age group ($60 years) to 12.7 in the youngest (15–29
years). The HR for HIV-2 infection varied from 1.2 (oldest) to 9.1 (youngest), and for HTLV-1 infection from 1.2 (oldest) to 3.8
(youngest).
Conclusions: HTLV-1 infection is associated with significantly increased mortality. The mortality rate of HIV-2 infection,
although lower than that of HIV-1 infection, is also increased, especially among young people.
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Introduction
HIV-1, HIV-2 and Human T-cell Lymphotropic Virus type 1
(HTLV-1) are all endemic in Guinea-Bissau. While HIV-1 in the
absence of treatment leads to AIDS and death in the vast majority
of infected individuals, only 50% of people with HIV-2 infection
are estimated to progress to AIDS and death [1]. HTLV-1 causes
a lethal form of leukaemia, Adult T-cell Leukemia, and a
debilitating neurological syndrome, Tropical Spastic Paresis, in
up to 5% of infected individuals and is associated with a number of
infectious and inflammatory conditions (reviewed in [2]). Reports
on mortality associated with HTLV-1 infection vary and do not
always find significantly increased mortality rates compared to
uninfected people (mortality rate ratios ranging from 1.1 to 1.9)
[3,4,5,6].
Dual infection with HIV-1 and HIV-2 is relatively common in
West Africa (reviewed in [7]) and most studies have found a similar
mortality in HIV-1 single infections and HIV-1/HIv-2 dual
infections, suggesting HIV-1 is the driving force in disease
progression. This was based on studies in clinical settings
[8,9,10] and only one community based study among older
individuals [5].
Dual infection with HIV-1 and HTLV-1 has been described
mainly in African and South-American countries and high-risk
patient groups (commercial sex workers and iv drug users) in
Europe [11,12,13]. Whether HTLV-1 co-infection leads to a faster
disease progression in HIV infection and what its effect is on
mortality remains unclear, because most studies were cross-
sectional and lacked control groups of singly HTLV-1 infected
people (reviewed in [14]). In Guinea-Bissau, HTLV-1/HIV-2 dual
infection is relatively common (12–20% of HIV-2 infected people)
[15,16,17,18]. Two studies examined the effect of co-infection and
did not observe an increased mortality in HTLV-1/HIV-2 co-
infected individuals compared to HIV-2 singly infected people
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[5,19], although one study did find a higher mortality in HTLV-
1/HIV-2 co-infected individuals with pulmonary tuberculosis as
compared to HIV-2 singly infected individuals [20]. A report from
the population in which the current study was performed found a
higher CD4% and a lower HIV-2 viral load in HTLV-1 infected
compared to HTLV-1 uninfected people, suggesting a potential
beneficial effect [19].
Caio´, the community described in this study, has had the
highest prevalence of HIV-2 (8%) in adults world-wide, has an
increasing HIV-1 prevalence (currently 4%) and the highest
HTLV-1 prevalence (5%) in adults in Guinea-Bissau [15,21]. We
examined the effects of retroviral single and dual infections on
mortality in a community based cohort in rural Guinea-Bissau
over a 20-year period.
Methods
Ethics Statement
All studies were approved by the Gambia Government/MRC
Laboratories Joint Ethics Committee and by the Ministry of
Health of Guinea-Bissau. Informed consent was obtained from all
the study participants. Local community spokesmen, representa-
tives of the Guinea-Bissau government and the local nurses and
physicians were always first informed about the planned studies,
after which village meetings were held to inform all Caio residents.
Prior to 2003 verbal informed consent was obtained from all study
participants. From 2003 onwards, written informed consent from
all study participants was obtained as required by the Gambian
Ethics Committee.
Study area and subjects
The study was conducted in a rural area in North-western
Guinea-Bissau, consisting of ten small settlements in a forest. The
population consists mostly of people from the Manjako ethnic
group. The main agricultural products are cashew nuts, cashew
wine, palm wine, palm oil, and rice. Since 1989 a demographic
database of the population has been maintained. Field workers
visit all compounds at least once a year to record changes (deaths,
births, moves, emigration, and immigration). When a person has
died in the compound, a basic questionnaire concerning the
conditions of the person prior to his/her death, is administered to
the closest relative by the fieldworker. Every village has a village
reporter who reports on vital events. Many men work and live in
large towns in the sub-region and in Europe, mainly in Portugal
and France. Because family links are very strong, news about
deaths abroad of people originating from the study area reliably
reaches the community. Also, a special ceremony is held after a
death of an adult which lasts 1–2 days and therefore we assume the
majority of deaths in the community are recorded accurately in
the census. More adult men than women spend time away,
creating a low men-women ratio. People who keep a room in their
house or compound, and who are expected to return, are
considered residents.
The current analysis comprises data of three population surveys
among adults carried out in 1989–1991, 1996–1998 and 2006–
2007, in which approximately 75% of all the residents were
included [15,21]. These study rounds will be referred to as 1990,
1997 and 2007 hereafter. HIV-positive and -negative individuals
identified in these surveys were then invited to join a cohort
Table 1. Baseline characteristics of 5376 adults by retroviral status, Caio´, 1989-2009.
HTLV-1 negative HTLV-1 positive
HIV nega HIV-1 pos HIV-2 pos HIV-1/2 posb HIV neg HIV-2 pos
HIV-1 or HIV-1/2
posc Total
Total number 4,797 55 235 14 200 61 14 5376
Number female (%) 2,801 (58) 30 (55) 151 (64) 12 (86)* 131 (66)* 54 (89)* 12 (86)* 3191 (59)
Median age (IQR) 25 (20–43) 31 (25–42) 44 (34–58)* 47 (35–60)* 42 (23–64)* 59 (45–67)* 48 (42–54)* 27 (20–47)
Age group (%)
15–29 2,878 (60) 26 (47)* 40 (17)* 1 (7)* 74 (37)* 3 (5)* – 3,022 (56)
30–44 785 (16) 20 (36)* 80 (34)* 6 (43)* 37 (19)* 12 (20)* 5 (36)* 945 (18)
45–59 502 (10) 5 (9)* 64 (27)* 3 (21)* 29 (15)* 17 (28)* 8 (57)* 628 (12)
60-max 632 (13) 4 (7)* 51 (22)* 4 (29)* 60 (30)* 29 (48)* 1 (7)* 781 (15)
Ethnic group Manjako (%) 4,561 (95) 49 (89) 218 (93) 12 (86) 189 (95) 60 (98) 14 (100) 5103 (95)
Central zone of living (%) 3,156 (66) 43 (78)* 184 (79)* 10 (71) 144 (73) 50 (82)* 10 (71) 3597 (67)
Marital status (%)
Single 2,223 (46) 18 (33)* 36 (15)* 1 (7)* 62 (31)* 4 (7)* 2 (14)* 2346 (44)
Married 2,314 (48) 29 (53)* 186 (71)* 5 (36)* 102 (51)* 30 (49)* 9 (64)* 2657 (49)
Widowed 201 (4) 6 (11)* 21 (9)* 6 (43)* 28 (14)* 21 (34)* 2 (14)* 285 (5)
Divorced 54 (1) 2 (4)* 10 (4)* 1 (7)* 8 (4)* 6 (10)* 1 (7)* 82 (2)
Number with only baseline
sample (%)d
2601 (54) 34 (62) 87 (37)* 9 (64)* 111 (56) 26 (43) 9 (64) 2877 (54)
Neg, negative; pos, positive; IQR, interquartile range; ranksum test for age, chi square for proportions of infected versus HIV and HTLV-1 uninfected individuals
( * = significant at 5% level).
a5 subjects had missing data for marital status.
b1 subject had missing data for marital status.
c5 subjects were HTLV-1/HIV-1 infected and 9 were HTLV-1/HIV-1/2 infected.
dplease see Van Tienen et al. JAIDS 2010 for the differences between subjects with and without a follow-up sample.
doi:10.1371/journal.pone.0029026.t001
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(matched by sex, age and area of living) which was initiated in
1991; members of this cohort were re-examined in 1996, 2003 and
2006.
Cohort members have free access to medication and medical
care provided by the physician who is based permanently at the
research project run by the Medical Research Council and the
Bandim Health Project in Caio. The project building houses a
laboratory, small pharmacy, consultation room and administrative
offices. Anti-retroviral treatment for HIV became available in
2007 as part of the national AIDS program, after completion of
the 2007 survey.
Laboratory methods: HIV testing
HIV testing methods have been described [21,22]. In brief, in
the 1990 survey the HIV diagnoses were determined by serology
(Murex Diagnostics, Dartford, UK) and most of these samples
were confirmed by PCR in a follow-up study in 1991 [22]. In the
1997 survey the following algorithm was used: plasma samples
were first screened by ELISA (Murex Diagnostics, Dartford, UK),
reactive samples were then tested by ELISAs that are mono-
specific for HIV-1 and HIV-2 (Wellcozyme 1, Wellcozyme II and
ICEHIV-2, Murex Diagnostics, Dartford, UK) and by a synthetic
peptide-based assay (Pepti-Lav, Pasteur, France). Dually reactive
and indeterminate samples underwent PCR for confirmation [23].
In the 2007 survey, plasma samples were first screened by ELISA
(Murex Diagnostics, Dartford, UK). Subsequently, HIV-1 or HIV-
2 confirmation was obtained using a synthetic peptide-based assay
(Hexagon, Human, Germany). Dually reactive and indeterminate
samples were subjected to a different synthetic peptide-based assay
(Pepti-Lav 1-2, Sanofi Diagnostics, France). Indeterminate results
were resolved using HIV-1 and HIV-2-specific PCR [21].
Laboratory methods: HTLV testing
For the 1990 survey, two different screening ELISAs (Organon
Teknika, Boxtel, The Netherlands and Murex HTLV-1/2,
Abbott/Murex Diagnostics, Dartford, UK) were used and positive
samples were confirmed by PCR and/or Western Blot as
described [18,19]. For the 1997 and 2007 survey, an ELISA
(Murex I/II, Abbott Murex Diagnostics, Dartford, UK) was used
to screen all samples. Reactive samples were retested with the
same ELISA (Murex I/II, Abbott Murex Diagnostics, Dartford,
UK) and were confirmed by PCR using primer pairs derived from
the tax/rex gene for the 1997 samples [24] and by nested PCR
using primers targeted to either the gag p24 open reading frame or
to the tax gene for the 2007 samples [15]. These primers were
specific for HTLV-1. As a control for DNA quality, all samples
testing negative for both p24 and tax PCR were tested for presence
of human DNA, using primers against the human beta-2-
microglobulin gene and all were positive. Subjects were considered
HTLV-1 infected if at least one of the 2 ELISAs was reactive and
either PCR or Western Blot was positive.
Statistical Methods
Analysis was done using Stata 11 (Stata Corporation, College
station, TX, USA). Differences in categorical variables were
examined by chi-square test or Fisher’s exact test. When age was
treated as a continuous variable, differences between groups were
examined by Wilcoxon’s ranksum test.
The information collected during the first survey at which a
person participated in the study (this could be either in 1990, 1997
or 2007), was used as baseline information.
Survival probability was examined by Kaplan-Meier (KM)
graphs. The follow-up time started on the date when subjects were
first enrolled with interview and blood sample (i.e. in the survey inT
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1990, 1997 or 2007) and ended on the date of death, or on the
date of moving out of the area with no more information being
available for the subject ( = loss to follow-up) or on the date they
were last known to be alive during the last census (2009), or on the
date they were tested positive for a different retroviral infection, or
on the date subjects started anti-retroviral treatment (ART),
whichever came first. After seroconversion, the observation time
would start again from time 0. This means that subjects who
seroconverted contributed to more than one retroviral group.
Cox regression was used to calculate mortality Hazard Ratios
(HR). The proportional hazard’s assumption was assessed
graphically and by statistical testing (Schoenfeld residuals). Age
was used as a categorical variable with 4 age groups. Age and
retroviral status were treated as time-varying variables. In the
multivariable analysis, all baseline variables from the univariate
analysis were entered into an initial model. Variables were then
dropped one by one if they were not significant predictors of
mortality and if their omission did not change the HR of the HIV
and HTLV-1 status variables in a substantial way ($10%). Models
were compared with likelihood ratio tests (LRT) and the Wald test
was used to compare model parameters (Hazard Ratios).
The STROBE guidelines were used to report the findings of this
study in this paper [25].
Results
Subjects
In total, 5,822 subjects provided a blood sample in one or more
of the three study rounds (in 1990, 1997 and 2007). Of these, 446
(8%) subjects were excluded from the analysis due to: age ,15
years (n = 30, 7%), no re-identification of subject possible (n = 66,
15%), no census follow-up after a subject had participated for the
first time in the 2007 study round (n= 105, 24%), and
indeterminate or missing test results due to insufficient blood
volume for testing of all retroviral infections (n = 245, 55%). The
total number of subjects that had a final HIV and HTLV-1 result,
at one or more study rounds, was 5,376 (Table 1).
The baseline characteristics are listed in Table 1. Among the
HTLV-1 uninfected, at baseline there were 55 (1%) HIV-1, 235
(4%) HIV-2 and 14 (0.3%) HIV-1/2 dually infected subjects.
Among the HTLV-1 infected, 200 (4%) subjects were singly
HTLV-1 infected, 61 (1%) subjects were HTLV-1/HIV-2 dually
infected and 14 (0.3%) were HTLV-1/HIV-1 dually or HTLV-1/
HIV-1/2 triply infected. The median age at enrolment was 27
years (interquartile range, 20-47). Most subjects were Manjako
(n= 5,103; 95%), which was similar for the various retroviral
infected groups. Individuals infected with HIV-2 and/or HTLV-1
or HIV-1 and HIV-2, were older and a higher percentage was
female compared to the uninfected group. Retroviral infected
subjects were less often single and more often divorced or widowed
compared to the uninfected subjects.
Follow-up
The follow-up details by retroviral status are listed in Table 2.
During follow-up, 40 subjects acquired HTLV-1 and 169 subjects
acquired HIV-1 and/or HIV-2. These seroconverters contribute
to more than one column in Table 2. The median observation
time was 10.9 years (range 4 days – 20.3 years). A total of 177 (3%)
people were lost to follow-up, 24 (0.4%) people started anti-
retroviral treatment (ART) and a total of 1089 (20%) persons died.
The overall mortality rate was 2.0 (95% CI 1.9–2.1) per 100
person years of observation.
The lay reports of symptoms and conditions before death are
given in Table 3. Symptoms that may be associated with
immunosuppression, such as diarrhea, cough or respiratory
problems, high fever and vomiting were more common in HIV
infected than HIV uninfected individuals that died, especially
among HIV-1 and HIV-1/2 infected people.
Mortality proportional hazard analysis
The univariate HR for mortality was significantly increased for
all retroviral infection groups (p,0.001), compared to the
uninfected group (Table 4). Differences in sex, age group, marital
status and calendar period significantly influenced the HR.
Ethnicity and zone of living were not associated with increased
mortality. When 25 HIV-2 positive people with a history of blood
transfusion were excluded, because this may be related to a worse
health condition or a higher viral load, this did not change the HR
for HIV-2.
Differences in survival between retroviral infection groups can
be observed in Figures 1a and 1b. The survival probability differed
significantly between each retroviral infection group and the
Table 3. Signs and symptoms related to 1089 deaths among adults by retroviral status, Caio´, 1989–2009.
HTLV-1 negative HTLV-1 positive
Symptoms/signsa HIV neg HIV-1 pos HIV-2 pos HIV-1/2 pos HIV neg HIV-2 pos
HIV-1 or HIV1/2
pos
Total number of deaths 786 43 111 24 73 33 19
Number of women 415 (52.8) 21 (48.8) 57 (51.4) 21 (87.5)* 45 (61.6) 30 (90.9)* 17 (89.5)*
Diarrhea 23 (3.0) 8 (18.6)* 6 (5.5) 7 (29.2)* 4 (5.5) 2 (6.1) 1 (5.3)
Cough/respiratory problems 29 (3.7) 9 (20.9)* 10 (9.0)* 5 (20.8)* 3 (4.1) 5 (15.2)* 1 (5.3)
High fever 84 (10.8) 14 (32.6)* 17 (15.5) 8 (33.3)* 13 (17.8) 4 (12.1) -
Vomiting 17 (2.2) 5 (11.6)* 6 (5.5)* 3 (12.5)* 4 (5.5) 3 (9.1)* -
Paralysis 20 (2.6) 1 (2.3) 3 (2.7) - 1 (1.4) 1 (3.0) -
Hospitalized 179 (23.0) 25 (58.1)* 38 (34.6)* 9 (37.5) 16 (21.9) 8 (24.2) 8 (42.1)*
Accidentb 34 (4.3) - 3 (2.7) - 3 (4.1) 1 (3.0) -
Neg, negative; pos, positive; chi-square for proportions of infected versus uninfected individuals (* = significant at 5% level).
aplease note that individuals could have more than one sign or symptom (so numbers of deaths do not match the total numbers of symptoms and signs).
bdrowning, snake bite, fall from/hit by tree, car accident, suicide.
doi:10.1371/journal.pone.0029026.t003
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uninfected group (logrank test, p,0.001), between HIV-1 and
HIV-2 (p,0.001), between HIV-1/2 dually and HIV-2 (p,0.001)
and between HTLV-1/HIV-2 dually and HTLV-1 infected
subjects (p = 0.03).
In the multivariable model, HIV status, HTLV-1 status, sex,
age and marital status remained significantly associated with
mortality and were included. All possible interactions between the
two main exposures, HIV and HTLV-1 status, and the other
variables were tested. Strong and significant interactions were
found between HIV and age (LRT, p,0.001) and between
HTLV-1 and age (p = 0.01). HRs are reported stratified by age
(Table 5). Strikingly, in HIV-2 and HTLV-1 infection, the HRs
were highest (and highly significant) in the youngest age category
(15-29 years), 9.1 and 3.8 respectively, and decreased with age, to
1.2 and 1.2 in the 60+ age group (both non-significant). Also in
HIV-1 and HIV-1/2 dually infected individuals, the lowest HRs
were observed in the oldest age group, being 4.0 and 3.3,
respectively (p = 0.002 and p,0.001, respectively). The age-
stratified HRs of HIV-1 and HIV-1/HIV-2 dual infection were
not significantly different (Wald test, p.0.4 for all age groups).
Discussion
Key findings
This cohort study has confirmed an increased risk of death
among HIV-1, HIV-2 and HTLV-1 infected individuals compared
to uninfected individuals in a rural area of Guinea-Bissau. To our
knowledge, this is the largest and longest community based study
that has examined the effects of infection with these three
retroviruses on mortality. Notably, this population had an excellent
follow-up and was ART-naı¨ve during the study and therefore the
observed mortality reflects the natural effect of these retroviral
infections on mortality. The highest mortality was observed in HIV-
1 and HIV-1/2 dually infected individuals and the age-stratified
HRs were similar in these infection groups. HIV-2 and HTLV-1
infected subjects had a more moderately increasedmortality and the
highest HR was observed in the youngest subjects.
HIV related mortality
The more than 10-fold increase in mortality rate of HIV-1, as
observed in all age groups except the oldest, is in line with
community based studies from other parts of Africa, where
similarly increased mortality rates have been observed [26]. It is
higher than the 5-fold increase that was found in a study from the
capital Bissau, which may be related to the older age and a higher
loss to follow-up in the Bissau cohort [5].
This study confirms the increased mortality rate in HIV-2
infection, observed in previous analyses from this study population
[27,28] and other community based studies [5,29]. Generally, the
HR was lower than the HR (3.5) observed in the same cohort in
1991–1993 [28]. In the Bissau cohort, a higher HR was also
observed in the first year of follow-up which then decreased during
subsequent observation [29]. This could be related to the fact that
those subjects that are unable to control the infection will have died,
leaving a majority of long-term survivors among the HIV-2 positive
subjects, who have a lower HR. The HR declined with increasing
age. This is probably due to two factors: a higher background
mortality among older individuals and a survival bias of a group of
older individuals that are not progressing to disease. In HIV-2
infection, certain individuals control the virus, maintaining low viral
loads for prolonged periods of time, and have a normal lifespan
[30], while others progress rapidly and contribute to the observed
excess mortality. Understanding the biological mechanisms behind
this phenomenon could lead to better understanding of HIV control
by the immune system and could contribute to vaccine development
for both HIV-1 and HIV-2.
The HRs of HIV-1 and HIV-1/2 dually infected subjects were not
significantly different from each other in this study. Several studies
have observed that mortality rates amongHIV-1 singly andHIV-1/2
dually infected individuals are similar [5,8,9,10], suggesting HIV-1
determines the outcome of the infection on mortality. The lower HRs
observed in the oldest individuals is probably related to the higher
background mortality in this age group.
HTLV-1 related mortality
An increased mortality rate with HTLV-1 infection was
observed. The effect of this infection on mortality was independent
Table 4. Univariate Mortality Hazard Ratios of adults, Caio´,
1989–2009.
Mortality Hazard Ratio
(95% CI) p-value
HIV/HTLV-1 status
HIV/HTLV-1 neg 1 ,0.001
HTLV-1 negative:
HIV-1 pos 7.3 (5.3–10.0)
HIV-2 pos 2.6 (2.1–3.2)
HIV-1/2 dual pos 6.6 (4.4–9.9)
HTLV-1 positive:
HIV neg 2.3 (1.8–2.9)
HIV-2 pos 3.7 (2.6–5.3)
HIV-1 or HIV-1/2 12.4 (7.8–19.6)
Sex
Male 1 ,0.001
Female 0.7 (0.7–0.8)
Age group
15–29 1 ,0.001
30–44 2.6 (2.0–3.4)
45–59 4.8 (3.7–6.4)
60-max 15.2 (11.9–19.5)
Marital status
Single 1 ,0.001
Married 2.0 (1.7–2.4)
Divorced 5.2 (4.2–6.3)
Widowed 6.6 (5.2–8.3)
Ethnic group
Manjako 1 0.1
Other 0.8 (0.5–1.1)
Zone of living
Central 1 0.4
Periphery 0.9 (0.8–1.1)
Time period
1989–1993 1 0.05
1994–1998 1.4 (1.1–1.8)
1999–2003 1.2 (0.9–1.5)
2004–2009 1.1 (0.8–1.4)
CI, confidence interval; neg, negative; pos, positive.
doi:10.1371/journal.pone.0029026.t004
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from the mortality effect of HIV-2. Thus the increased mortality
rate among co-infected people is the result of the increase in
mortality due to HIV-2 infection and due to the increase in
mortality due to HTLV-1 infection; there are no indications that
co-infection leads to a more rapid disease progression of HIV-2.
This is in agreement with a study performed in a subset of this
population, which found that there was no enhancing effect of
HTLV-1 co-infection on the replication of HIV-2 in vivo [19].
HTLV-1 is associated with an increased CD4 count, also in HIV-2
infection, but this does not seem to result in a better outcome of
the infection [19].
What causes this increased mortality among usually asymptom-
atic carriers of HTLV-1? A case-control study performed in Caio´
showed a prevalence of 7.1% of probable Tropical Spastic Paresis
in HTLV-1 infected subjects [31] and the incidence of Adult T-
cell Leukemia is not known. A number of infectious and
inflammatory conditions have been associated with HTLV-1
infection in the past decades, that may be related to altered
immune responses (reviewed in [2]). Cross-sectional and case-
control studies have shown an increase of TB in HTLV-1 infection
[32]. From the lay reports of symptoms before death in the current
study, there was no indication that cough or respiratory symptoms
were more frequent among HTLV-1 single infected individuals,
but that it was elevated among HTLV-1/HIV-2 dually infected
individuals. This would be in line with a study from Bissau where a
higher prevalence of HTLV-1 was found among HIV-positive TB
patients, but not among HIV-negative TB patients [33], but would
not explain the independent increased risk of death among
HTLV-1 single infected individuals observed in this study. No
formal studies have been conducted in Caio´ to determine the
incidence of TB and the death reports were entirely done by lay
field workers and therefore need to be interpreted with caution.
Figure 1. A. Kaplan-Meier graph of survival probability by HIV-status for subjects from Caio´, 1989–2009 (HTLV-1 infected subjects excluded). B.
Kaplan-Meier graph of survival probability by HTLV-1 and HIV-2 infection status for subjects from Caio´, 1989–2009 (HIV-1 and HIV-1/2 infected
subjects excluded).
doi:10.1371/journal.pone.0029026.g001
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Gender specific mortality
HIV-2 single and dual infections are more common among
women than men (reviewed in [34]) and the prevalence increases
with age. One reason for this observed difference may be a gender
specific difference in mortality. In the current study we found that
in our total population the crude (or unadjusted) mortality was
significantly lower among women than men (MRR 0.7, CI 0.7–
0.8). This is most likely related to the fact that non-HIV related
mortality is usually higher in men than in women [35]. In the
multivariable analysis however, there was no modifying effect of
sex on mortality, i.e. there was no interaction between sex and
mortality. Hence, there is no higher mortality among men that
could explain the difference in retroviral prevalence. Increased
sexual risk behavior has not been proven to explain this difference
either [36]. Other possible explanations are an increased
susceptibility of older women due to changes in the vaginal
mucosa [34,37].
Public health implications
This study was performed in a treatment-naı¨ve population,
where HIV and HTLV-1 infection are endemic. Although
antiretroviral treatment became available in 2005 in the capital,
the treatment in Caio´ only started in 2007. HIV/HTLV-1 co-
infection is associated with increased CD4 counts [14,19,20],
which complicates the decision when to start treatment. The
intermittent antiretroviral drug supply also poses many difficulties
in the treatment of HIV patients in Guinea-Bissau [38]. Although
national programs are in place for prevention of transmission, this
is mainly limited to the capital and is not fully operational in rural
areas like Caio´. Despite local efforts to educate the Caio´
community about HIV - e.g. through village meetings, free
distribution of condoms, NGO prevention programs - HIV-1
increased during the study period [21]. It is crucial that public
health efforts are made to prevent HIV and HTLV-1 transmission
and to give appropriate care to infected individuals.
Limitations
Due to the long intervals between the study rounds, the time of
infection of the subjects in this study were unknown. A follow-up
sample was available for 46% of the subjects. In this group,
seroconversions could be established, but in people without
subsequent samples unchanged retroviral status was assumed in
the analysis. This will have led to an underestimation of the HRs;
for example, some subjects that were HIV-negative at baseline will
have seroconverted and died while contributing to the uninfected
group. Among the HIV-2 (and possibly HTLV-1) infected
individuals the incidence of HIV-1 is higher than among
uninfected individuals [23]. Thus it is possible that the mortality
among HIV-2 (and HTLV-1) infected persons is overestimated in
this study, although the number of persons with a follow-up
sample(s) among HIV-2 infected people was higher (63%) than
among the other groups (Table 1).
Conclusion
To our knowledge, this is the largest community cohort study to
examine the combined effects of HIV-1, HIV-2 and HTLV-1 on
Table 5. Adjusted Mortality Hazard Ratios of adults by retroviral infection, stratified by age and sex, Caio´, 1989-2009.
Adjusted Mortality Hazard Ratio (95% CI)
Age group N deaths/N subjectsa Men and womenb Menc Womenc
HIV-1
15–29 4/38 12.7 (4.5–35.6) - 21.4 (7.1–64.0)
30–44 22/72 13.9 (8.5–22.7) 11.7 (6.1–22.3) 15.4 (7.2–33.2)
45–59 17/37 15.2 (8.6–26.7) 10.9 (4.5–26.1) 19.2 (9.2–40.2)
60-max 5/12 4.0 (1.6–9.7) 3.2 (1.0–10.1) 6.1 (1.5–25.1)
HIV-2
15–29 6/54 9.1 (3.8–21.7) - 16.6 (6.4–43.3)
30–44 24/145 3.6 (2.3–5.6) 2.6 (1.3–5.2) 4.4 (2.4–8.2)
45–59 38/168 2.5 (1.7–3.6) 2.1 (1.2–3.7) 3.0 (1.8–5.1)
60-max 76/157 1.2 (0.9–1.5) 1.4 (0.9–2.0) 1.1 (0.8–1.5)
HIV-1/2 dual
15–29 1/6 29.2 (3.9–217.0) - 88.8 (10.7–738.0)
30–44 9/27 10.2 (5.0–20.6) 6.7 (2.1–21.7) 13.7 (5.5–33.9)
45–59 13/37 11.4 (6.1–21.2) 4.7 (0.6–34.4) 15.2 (7.5–30.6)
60-max 15/25 3.3 (1.9–5.5) - 3.3 (1.9–5.6)
HTLV-1
15–29 7/86 3.8 (1.7–8.5) 4.5 (1.8–11.7) 2.0 (0.4–9.2)
30–44 14/97 2.3 (1.3–4.1) 2.0 (0.6–6.3) 2.2 (1.1–4.5)
45–59 20/101 1.4 (0.9–2.3) 1.5 (0.5–4.0) 1.4 (0.8–2.5)
60-max 84/150 1.2 (0.9–1.5) 0.9 (0.5–1.4) 1.3 (1.0–1.8)
CI, confidence interval.
aNumber of deaths among retroviral positive subjects/Number of retroviral positive subjects – NB subjects can contribute to more than one age group because age was
treated as a time-varying variable.
badjusted for all other retroviral infections, marital status, sex.
cadjusted for all other retroviral infections, marital status.
doi:10.1371/journal.pone.0029026.t005
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mortality. The occurrence and size of the excess mortality in both
HIV infections can be explained by AIDS and is in line with other
studies. The excess mortality associated with HTLV-1 reported in
other studies is confirmed in this study, but its causes remain to be
elucidated.
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